{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:56Z","timestamp":1791685376415,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Laboratoires SMB"},{"name":"AstraZeneca Pharmaceuticals LP"},{"name":"Genzyme Corporation"},{"name":"Kowa Pharmaceuticals America, Inc"},{"name":"Laboratoires SMB"},{"DOI":"10.13039\/100004334","name":"Merck & Co, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck\/Schering-Plough"},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Pfizer Inc"},{"name":"Recordati"},{"name":"The sanofi-aventis Group"},{"name":"Solvay Pharmaceuticals GmbH"},{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.clinthera.2011.02.006","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T15:55:11Z","timestamp":1300290911000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Fixed-Dose Combination Fenofibrate\/Pravastatin 160\/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study"],"prefix":"10.1016","volume":"33","author":[{"given":"Michel","family":"Farnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Retterst\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Cs\u00e1sz\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.02.006_bib1","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary","volume":"28","author":"Ryd\u00e9n","year":"2007","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.02.006_bib2","first-page":"S4","article-title":"Executive summary: Standards of medical care in diabetes\u20142010","volume":"33","year":"2010","journal-title":"Diabetes Care"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2011.02.006_bib3","doi-asserted-by":"crossref","first-page":"1K","DOI":"10.1016\/j.amjcard.2008.10.002","article-title":"The Residual Risk Reduction Initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia","volume":"102","author":"Fruchart","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib4","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.02.006_bib5","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.02.006_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2011.02.006_bib7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2165\/00129784-200303030-00003","article-title":"Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: A critical review of potential benefits and drawbacks","volume":"3","author":"Farnier","year":"2003","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2011.02.006_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2003.11.012","article-title":"Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia","volume":"64","author":"Durrington","year":"2004","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2011.02.006_bib10","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1185\/03007990903073159","article-title":"Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients","volume":"25","author":"Derosa","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2011.02.006_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJM196701052760107","article-title":"Fat transport in lipoproteins\u2014An integrated approach to mechanisms and disorders","volume":"276","author":"Fredrickson","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.02.006_bib12","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/clinchem\/32.6.957","article-title":"Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum","volume":"32","author":"Rifai","year":"1986","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2011.02.006_bib13","series-title":"Common Statistical Methods for Clinical Research","article-title":"Analysis of covariance","author":"Walker","year":"2002"},{"key":"10.1016\/j.clinthera.2011.02.006_bib14","first-page":"S25","article-title":"Diabetic dyslipidaemias","volume":"36","author":"Betteridge","year":"1999","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: From basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2011.02.006_bib16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib17","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.02.006_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2011.02.006_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/00912700022008874","article-title":"Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers","volume":"40","author":"Pan","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib21","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/0091270005278085","article-title":"The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite","volume":"45","author":"Gustavson","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.amjcard.2010.05.005","article-title":"Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy","volume":"106","author":"Farnier","year":"2010","journal-title":"Am J Cardiol"},{"issue":"Suppl 9A","key":"10.1016\/j.clinthera.2011.02.006_bib23","doi-asserted-by":"crossref","first-page":"44K","DOI":"10.1016\/j.amjcard.2005.08.007","article-title":"Pharmacokinetic interactions between statins and fibrates","volume":"96","author":"Corsini","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2009.151","article-title":"Myopathy with statin-fibrate combination therapy: Clinical considerations","volume":"5","author":"Jacobson","year":"2009","journal-title":"Nat Rev Endocrinol"},{"issue":"Suppl 6A","key":"10.1016\/j.clinthera.2011.02.006_bib25","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2011.02.006_bib26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2147\/VHRM.S3390","article-title":"Update on the clinical utility of fenofibrate in mixed dyslipidemias: Mechanisms of action and rational prescribing","volume":"4","author":"Farnier","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2011.02.006_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-200767010-00013","article-title":"Fenofibrate: A review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus","volume":"67","author":"Keating","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2011.02.006_bib28","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9975 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.02.006_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811000889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811000889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:38Z","timestamp":1758962918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811000889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0149291811000889"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.02.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fixed-Dose Combination Fenofibrate\/Pravastatin 160\/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}